Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2005
10/05/2005CN1221261C Flunarizine hydrochloride high-capacity injecta and preparing process thereof
10/05/2005CN1221258C Application of bendazac lysine in the preparing process of medicine for preventing and treating diabetic nephropathy
10/05/2005CN1221256C 药物组合物 The pharmaceutical composition of
10/05/2005CN1221252C Process for preparing slow-releasing indapamide tablet
10/05/2005CN1221251C Foot refreshing powder
10/05/2005CN1221250C Use of particulate contrast agents in diagnostic imaging for studying physiological parameters
10/05/2005CN1221249C Injectable aqueous dispersions of propofol
10/05/2005CN1221248C Preparation method for antibiotics composition
10/05/2005CN1221246C Use of medicine having chemical compound for promoting collagen synthesizing activity
10/05/2005CN1221237C Composition for treatment of scars skin disease
10/05/2005CN1221214C Apparatus and method for making gas-filled utricle of optimal size
10/05/2005CN1221190C Composition and method for smoke detoxification
10/05/2005CN1221179C Chewing gum composition
10/04/2005US6951902 Two dimensional polymer that generates nitric oxide
10/04/2005US6951885 Pharmaceutical composition
10/04/2005US6951845 Method for treating allergic lung disease
10/04/2005US6951842 solubilizing compound comprising a guanidinium group provides high concentrations of soluble insulin-like growth factor at pH 5 to 9 and at refrigerated temperatures
10/04/2005US6951841 Bioavailability; side effect reduction
10/04/2005US6951756 Closure of bacterial ghost
10/04/2005US6951658 administering mixtures of animal oils, lioleic acid, arginine, pyroglutamic acid, methyl vitamin B12 and calcium, for prophylaxis of neurodegenative diseases
10/04/2005US6951657 Particles coated with granulated crystalline ibuprofen
10/04/2005US6951656 Microprecipitation method for preparing submicron suspensions
10/04/2005US6951655 Comprises liposome core containing drugs (insulin) encapsulated within fatty acid membrane
10/04/2005US6951654 Intravaginal drug delivery devices for the administration of an antimicrobial agent
10/04/2005US6951642 Water-in-oil emulsions with anionic groups, compositions, and methods
10/04/2005CA2166101C Drug delivery
10/04/2005CA2137017C Controlled release pharmaceutical tablet having lenticular form
10/04/2005CA2117761C Pharmaceutical compositions containing il-6
09/2005
09/29/2005WO2005090461A2 Thermoplastic films and methods for making
09/29/2005WO2005090445A1 Matrix of polysaccharide that is modified under an electron beam by a functional oganosilicon compound
09/29/2005WO2005090408A1 Native plant cell wall compositions and methods of use
09/29/2005WO2005089927A1 Polymer-stabilised, crystallised, catanionic membranes, preparation method thereof and applications of same
09/29/2005WO2005089926A1 Method for producing coated fine particles
09/29/2005WO2005089814A1 X-ray visible drug delivery device
09/29/2005WO2005089806A1 Cream-gel containing ivermectin
09/29/2005WO2005089797A2 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances
09/29/2005WO2005089779A2 Rapidly disintegrating taste-masked tablet
09/29/2005WO2005089772A2 Prevention of loss of tight cell junctions using carbohydrate-containing compositions
09/29/2005WO2005089768A1 Intranasal benzodiazepine compositions
09/29/2005WO2005089740A1 Coenzyme q composition with long-term persistence in blood
09/29/2005WO2005089739A1 Medical emulsion of perfluororganic compounds and method for the production thereof
09/29/2005WO2005089729A2 Galenic formulations of organic compounds
09/29/2005WO2005089728A2 Means for transdermal administration of nicotine
09/29/2005WO2005089727A1 Method for producing cs particles and microcapsules using porous templates, cs particles and microcapsules, and the use thereof
09/29/2005WO2005089726A1 Pharmaceutical formulations
09/29/2005WO2005089725A2 Capsule for receiving at least one pharmaceutical composition, in particular for powder inhalators
09/29/2005WO2005089724A1 Effervescent formulations comprising desmopressin
09/29/2005WO2005089723A1 Drug delivery system based on polyethylene vinylacetate copolymers
09/29/2005WO2005089722A1 Rapid acting drug delivery compositions
09/29/2005WO2005089721A1 In process conversion method for preparing tannate tablet, capsule or other solid dosage forms
09/29/2005WO2005089720A1 Valsartan tablets and the process for the preparation thereof
09/29/2005WO2005089719A1 Polish compositions
09/29/2005WO2005089718A2 Pharmaceutical compositions
09/29/2005WO2005089717A1 Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
09/29/2005WO2005089716A1 Preparation with elevated content
09/29/2005WO2005089715A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2005089713A1 Application of a bioactive agent to a delivery substrate
09/29/2005WO2005089712A1 Lyophilization method to improve excipient crystallization
09/29/2005WO2005089711A2 Pharmaceutical formulation containing unmilled flutamide
09/29/2005WO2005089698A1 Pharmaceutical dispensing apparatus
09/29/2005WO2005089696A1 Pharmaceutical dispensing apparatus and method
09/29/2005WO2005089671A1 Implantable intravascular delivery device
09/29/2005WO2005089670A1 Pharmaceutical compositions for administration to a sinus
09/29/2005WO2005089611A1 A disposable nonwoven mitt
09/29/2005WO2005089503A2 Cd4-igg2 formulations
09/29/2005WO2005089472A2 Anti-adhesion spraying
09/29/2005WO2005089448A2 Administration of cisplatin by inhalation
09/29/2005WO2005089224A2 iRNA AGENTS TARGETING VEGF
09/29/2005WO2005089148A2 Delivery of genes encoding short hairpin rna using receptor-specific nanocontainers
09/29/2005WO2005077450A9 Intravascular delivery system for therapeutic agents
09/29/2005WO2005051350B1 Water dispersible tablet
09/29/2005WO2005049090A3 Olanzapine containing transdermal drug delivery compositions
09/29/2005WO2005042741A3 Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
09/29/2005WO2005041925A3 Compositions and dosage forms for enhanced absorption
09/29/2005WO2005039642A9 Dna delivery with gemini cationic surfactants
09/29/2005WO2005007107A3 Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
09/29/2005WO2004110346A3 Sustained release of antiinfectives
09/29/2005WO2004103315A3 Treatment of ophthalmic infections using antimicrobial peptides
09/29/2005WO2004099332A3 Wood adhesives containing solid residues of biomass fermentations
09/29/2005WO2004056314B1 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
09/29/2005WO2004012662A3 Improved treatment of cancer with glutamine
09/29/2005US20050216959 Using biobolistic electric discharge particle acceleration to transfer gold coated beads into cells; improving heterologous gene transfer and expression
09/29/2005US20050215991 Cardiac drug delivery system and method of use
09/29/2005US20050215982 RF medical device
09/29/2005US20050215934 Medicinal patch that leaves less adhesive residue when removed
09/29/2005US20050215722 Drug delivery compositions and medical devices containing block copolymer
09/29/2005US20050215650 Complex emulsions of perfluoropolyethers
09/29/2005US20050215643 A fast-release diclofenac dosage or its alkali salt in the form of a packet of powder for dissolving or suspending in water, a bilayered tablet that has a fast and a slow release layer, or a liquid drop solution; improving the taste/reducing side effects by the addition of an alkali bicarbonate; times
09/29/2005US20050215620 Method of treating amyloid beta precursor disorders
09/29/2005US20050215615 Medical compositions for intravesical treatment of bladder cancer
09/29/2005US20050215593 Kaposi's sarcoma; Crohn's disease
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215522 Blocks passage of the pathogen through lipid rafts in the membrane of a cell susceptible to the pathogen; especially for reducing the risk of infection with an enveloped immunodeficiency virus, T lymphotrophic virus or herpesvirus
09/29/2005US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
09/29/2005US20050215515 Viscoelastic composition, method of use and package
09/29/2005US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens
09/29/2005US20050215485 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
09/29/2005US20050215475 Transmucosal delivery of peptides and proteins
09/29/2005US20050215467 Multimeric Apo A-I agonist compounds
1 ... 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 ... 2991